Clin2Atlas
AtlasOther conditionsUrinary diseases and male infertility

Benign prostatic hyperplasia

3Curable in someAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020251990 — Doxazosin approved (FDA)1992 — Finasteride approved (FDA)1997 — Tamsulosin approved (FDA)2001 — Dutasteride approved (FDA)2002 — Tadalafil approved (FDA)2003 — Alfuzosin approved (FDA)2008 — Silodosin approved (FDA)
1990: Drug approval — Doxazosin approved (FDA). 1992: Drug approval — Finasteride approved (FDA). 1997: Drug approval — Tamsulosin approved (FDA). 2001: Drug approval — Dutasteride approved (FDA). 2002: Drug approval — Tadalafil approved (FDA). 2003: Drug approval — Alfuzosin approved (FDA). 2008: Drug approval — Silodosin approved (FDA)

What's being tested now

2014: 1 trials started2015: 1 trials started2016: 1 trials started2017: 2 trials started2018: 1 trials started2019: 2 trials started2020: 3 trials started2021: 4 trials started2022: 11 trials started2023: 10 trials started2024: 32 trials started2025: 38 trials started2026: 72 trials started2020202672

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 168 active Benign Prostatic Hyperplasia trials on Clin2 →

Related

Urinary tract infections and interstitial nephritisUrolithiasisMale infertilityOther urinary diseases

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.